These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18430496)

  • 41. Henoch-Schönlein purpura and meningococcal B vaccination.
    Sexton K; McNicholas A; Galloway Y; Radke S; Kieft C; Stehr-Green P; Reid S; Neutze J; Drake R
    Arch Dis Child; 2009 Mar; 94(3):224-6. PubMed ID: 18650242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination vaccines: postlicensure safety evaluation.
    Chen RT; Pool V; Takahashi H; Weniger BG; Patel B
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S327-33. PubMed ID: 11709768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Near real-time vaccine safety surveillance with partially accrued data.
    Greene SK; Kulldorff M; Yin R; Yih WK; Lieu TA; Weintraub ES; Lee GM
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):583-90. PubMed ID: 21538670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of vaccine surveillance data in the evaluation of safety of vaccines.
    Postila V; Kilpi T
    Vaccine; 2004 May; 22(15-16):2076-9. PubMed ID: 15121327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
    ;
    Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 49. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic.
    Lennon D
    N Z Med J; 2008 Mar; 121(1270):110-2. PubMed ID: 18364765
    [No Abstract]   [Full Text] [Related]  

  • 50. Reporting of adverse events following immunization in Australia.
    Isaacs D; Lawrence G; Boyd I; Ronaldson K; McEwen J
    J Paediatr Child Health; 2005 Apr; 41(4):163-6. PubMed ID: 15813867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception.
    Bines JE; Patel M; Parashar U
    J Infect Dis; 2009 Nov; 200 Suppl 1():S282-90. PubMed ID: 19817611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
    Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
    Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccine efficacy determination.
    Broome CV
    NIPH Ann; 1991 Dec; 14(2):219-21; discussion 222-4. PubMed ID: 1812435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM; Edwards IR; Savage RL
    N Z Med J; 1990 Mar; 103(885):98-100. PubMed ID: 2314744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Syncope after vaccination--United States, January 2005-July 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 May; 57(17):457-60. PubMed ID: 18451756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.